How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment

被引：0
作者：
Gupta, Sumit [1 ,2 ]
Maude, Shannon L. [3 ]
O'Brien, Maureen M. [4 ]
Rau, Rachel E. [5 ]
McNeer, Jennifer L. [6 ]
机构：
[1] Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, 555 Univ Ave, Toronto, ON M5G 1X8, Canada
[3] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[4] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA
[5] Texas Childrens Hosp, Baylor Coll Med, 1102 Bates St, Houston, TX 77030 USA
[6] Univ Chicago, Comer Childrens Hosp, 5841 S Maryland Ave, Chicago, IL 60637 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
B-ALL; children; blinatumomab; inotuzumab ozogamicin; tisagenlecleucel; ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; MINIMAL RESIDUAL DISEASE; INOTUZUMAB-OZOGAMICIN; CHILDREN; BLINATUMOMAB; SURVIVAL; THERAPY; RELAPSE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S11
页数：4
相关论文
共 32 条
  • [1] Angiolillo A, 2017, BLOOD, V130
  • [2] Bhojwani D, 2019, LEUKEMIA, V33, P884, DOI 10.1038/s41375-018-0265-z
  • [3] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
    Borowitz, Michael J.
    Wood, Brent L.
    Devidas, Meenakshi
    Loh, Mignon L.
    Raetz, Elizabeth A.
    Salzer, Wanda L.
    Nachman, James B.
    Carroll, Andrew J.
    Heerema, Nyla A.
    Gastier-Foster, Julie M.
    Willman, Cheryl L.
    Dai, Yunfeng
    Winick, Naomi J.
    Hunger, Stephen P.
    Carroll, William L.
    Larsen, Eric
    [J]. BLOOD, 2015, 126 (08) : 964 - 971
  • [5] A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study
    Brivio, Erica
    Lopez-Yurda, Marta
    Ownes, Cormac
    Diaz de Heredia, Cristina
    Bielorai, Bella
    Rossig, Claudia
    Van der Velden, Vincent
    Ammerlaan, Anneke C. J.
    van der Sluis, Inge M.
    Den Boer, Monique L.
    Chen, Ying
    Sleight, Barbara
    Brethon, Benoit
    Nysom, Karsten
    Stary, Jan
    Ora, Ingrid
    Chen-Santel, Christiane
    Vinti, Luciana
    Locatelli, Franco
    Zwaan, Christian Michel
    [J]. BLOOD, 2019, 134
  • [6] Brown PA, 2019, BLOOD, V134
  • [7] Burke M, 2017, PEDIAT BLOOD CANC, V64, P19
  • [8] Burke M, 2015, J CLIN ONCOL, V33
  • [9] Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    DiJoseph, JF
    Armellino, DC
    Boghaert, ER
    Khandke, K
    Dougher, MM
    Sridharan, L
    Kunz, A
    Hamann, PR
    Gorovits, B
    Udata, C
    Moran, JK
    Popplewell, AG
    Stephens, S
    Frost, P
    Damle, NK
    [J]. BLOOD, 2004, 103 (05) : 1807 - 1814
  • [10] Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
    Goekbuget, Nicola
    Zugmaier, Gerhard
    Klinger, Matthias
    Kufer, Peter
    Stelljes, Matthias
    Viardot, Andreas
    Horst, Heinz A.
    Neumann, Svenja
    Brueggemann, Monika
    Ottmann, Oliver G.
    Burmeister, Thomas
    Wessiepe, Dorothea
    Topp, Max S.
    Bargou, Ralf
    [J]. HAEMATOLOGICA, 2017, 102 (04) : E132 - E135
1234